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Abstract
Background: a-synuclein [a-Syn]-mediated activation of GSK-3b leading to increases in hyperphosphorylated Tau
has been shown by us to occur in striata of Parkinson’s diseased [PD] patients and in animal models of PD. In
Alzheimer’s disease, tauopathy exists in several brain regions; however, the pattern of distribution of tauopathy in
other brain regions of PD or in animal models of PD is not known. The current studies were undertaken to analyze
the distribution of tauopathy in different brain regions in a widely used mouse model of PD, the a-Syn
overexpressing mouse.
Results: High levels of a-Syn levels were seen in the brain stem, with a much smaller increase in the frontal
cortex; neither cerebellum nor hippocampus showed any overexpression of a-Syn. Elevated levels of p-Tau,
hyperphosphorylated at Ser202, Ser262 and Ser396/404, were seen in brain stem, with lower levels seen in
hippocampus. In both frontal cortex and cerebellum, increases were seen only in p-Ser396/404 Tau, but not in p-
Ser202 and p-Ser262. p-GSK-3b levels were not elevated in any of the brain regions, although total GSK-3b was
elevated in brain stem. p-p38MAPK levels were unchanged in all brain regions examined, while p-ERK levels were
elevated in brain stem, hippocampus and cerebellum, but not the frontal cortex. p-JNK levels were increased in
brain stem and cerebellum but not in the frontal cortex or hippocampus. Elevated levels of free tubulin, indicating
microtubule destabilization, were seen only in the brain stem.
Conclusion: Our combined data suggest that in this animal model of PD, tauopathy, along with microtubule
destabilization, exists primarily in the brain stem and striatum, which are also the two major brain regions known
to express high levels of a-Syn and undergo the highest levels of degeneration in human PD. Thus, tauopathy in
PD may have a very restricted pattern of distribution.
Background
a-Synuclein (a-Syn) is a presynaptic, ubiquitously
expressed protein in the brain, whose chief physiological
f u n c t i o nm a yb et h er e g u l a t i o no fs y n a p t i cl e v e l so f
dopamine and other monoamines through modulation
of the re-uptake function of monoamine transporters
[1]. Overexpression of a-Syn, through its gene duplica-
tion and triplication, is linked to idiopathic Parkinson’s
disease [2-6], while its A30P and A53T mutants cause
the autosomal dominant forms of familial PD [7,8]. In
pathological states, a-Syn misfolds into aggregates and
accumulates into neuronal inclusion bodies, termed
Lewy bodies (LBs), which are pathological hallmarks of
PD and other synucleinopathies [9-12]. Post-mortem
immunohistochemical studies show the presence of
hyperphosphorylated Tau (p-Tau), a protein normally
linked to the genesis of Alzheimer’sd i s e a s e( A D ) ,c o -
existing with a-Syn aggregates in the same neurons in
PD and other synucleinopathies [13-20]. Conversely, in
tauopathies such as AD, elevated levels of a-Syn have
been found [21-26], along with LBs [21,27,28].
M o r er e c e n t l y ,w eh a v es h o w ni nt h eM P T P / M P P
+ in
vivo and in vitro models of PD, respectively, that
increases in a-Syn can initiate and sustain p-Tau forma-
tion with hyperphosphorylation at Ser202, Ser262 and
Ser396/404, which are the same epitopes that are
* Correspondence: sidhua@georgetown.edu
1Department of Biochemistry and Molecular and Cell Biology, University of
California San Diego, La Jolla, California
Full list of author information is available at the end of the article
Kaul et al. BMC Neuroscience 2011, 12:79
http://www.biomedcentral.com/1471-2202/12/79
© 2011 Kaul et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.hyperphosphorylated in AD and lead to pathological
changes [29-32]. In PD, there was an absolute require-
ment for the presence of a-Syn in the induction of
hyperphosphorylation of Tau, and in MPTP-treated a-
Syn-/- mice or toxin-treated neuronal cells lacking a-
Syn we failed to observe any p-Tau formation [29,31],
suggesting that a-Syn is central to tauopathy. In addi-
tion, we also found increases in levels of active GSK-3b
[p-GSK-3b, hyperphosphorylated at Tyr216], a major
kinase known to hyperphosphorylate Tau at the above
mentioned sites. Blockade of this kinase with inhibitors
prevent a-Syn-mediated p-Tau formation [29,31,32],
thereby implicating p-GSK-3b in the mechanistic actions
of a-Syn.
More recently, we found tauopathy in striatum of both
the a-Syn overexpressing and the a-Syn A53T mutant
mouse models of PD [33,34]. In both studies, we found
Tau hyperphosphorylated at Ser202, Ser262 and Ser396/
404, which was accompanied by elevated levels of a-Syn
and p-GSK-3b. Interestingly, changes in p-Tau levels,
which bind to and stabilize microtubules, lead to desta-
bilization of the microtubule and actin networks in the
striatum [33], indicating that p-Tau formation increased
pathology in this brain region.
That tauopathy occurs in humans was confirmed
using postmortem striata from PD patients, where ele-
vated levels of a-Syn, p-Tau and p-GSK-3b were noted
[35]. Interestingly, such changes were seen only in the
striatum, but not in the inferior frontal gyrus of PD
patients, where, although increased levels of a-Syn were
noted, no changes in levels of p-Tau or p-GSK-3b were
observed. This suggested that unlike AD, where
tauopathy is seen throughout the brain, tauopathy in PD
may be limited to dopaminergic neurons and have a
more restricted pattern of distribution in the brain.
To further test this, the current studies were underta-
ken, whereby different brain regions of the a-Syn overex-
pressing mouse model of PD [36] were analyzed for
changes in a-Syn, p-Tau and Tau kinases; the brain
regions analyzed were brain stem, hippocampus, frontal
cortex and cerebellum. The data presented here show
that high levels of tauopathy, along with increases in a-
S y n ,a r eo b s e r v e di nb r a i ns t e m ,f o l l o w e db ym o r em o d -
est changes in hippocampus. In other brain regions
tested, increases were seen only in p-Ser396/404 Tau.
These tauopathic changes were independent of p-GSK-
3b and appeared to be mediated by p-JNK and/or p-ERK.
Results
Expression levels of a-Syn in different brain regions of
the PDGF-a-Syn overexpressing mice
We have previously [33] shown that a-Syn levels are
significantly [p < 0.05] elevated [by 113% compared to
litter-mate non-transgenic mice] in striata of PDGF-a-
Syn overexpressing mice and that such changes were
accompanied by profound tauopathy and increased
levels of p-GSK-3b, the kinase known to hyperpho-
sphorylate Tau at distinct epitopes. Increased levels of
a-Syn were similarly observed in postmortem striata of
PD and PD with dementia [35].
To assess whether a-Syn levels were also increased in
other brain regions of these transgenic mice, we exam-
ined brain stem, hippocampus, frontal cortex and cere-
bellum [Figure 1]. The highest levels of a-Syn were
Figure 1 Western blots of a-Syn levels in brain stem, hippocampus, frontal cortex, and cerebellum of PDGF-a-Syn overexpressing
transgenic mice. Brain stem [BS], hippocampus HP], frontal cortex [FC] and cerebellum [CVB] from PDGF-a-Syn transgenic mice and litter-mate
non-transgenic mice [WT] were solubilized in RIPA buffer and analyzed by Western blots for a-Syn levels. a-Syn was normalized to b-actin. All
values are expressed as percent change relative to changes observed in WT control animals. Results are from 3-4 animals per group; [*, p < 0.05]
and [**, p < 0.01] compared to corresponding brain regions in WT animals. All blots are representative of samples.
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Page 2 of 11observed in brain stem, where [p < 0.01] increases of
358% were noted. The brain stem is to undergo neuro-
degenerative changes in Parkinson’s disease [37], and
such large increases in a-Syn levels in this region may
parallel the pathological changes occurring in humans.
More modest increases in a-Syn levels in hippocampus
and frontal cortex were also noted, but they were signif-
icant only for the frontal cortex [15%, p <0 . 0 1 ] .I nt h e
cerebellum, a small insignificant decrease of ~30% in a-
Syn expression was seen [Figure 1].
Tauopathic changes in different brain regions of the
PDGF-a-Syn overexpressing mice
In striata of the PDGF-a-Syn overexpressing mouse
[33] as well as in striata of postmortem PD brains [35],
high levels of tauopathy were previously detected
where increases in p-Tau hyperphosphorylated at
Ser202, Ser262 and Ser396/404 were observed. In the
current study, the highest levels of tauopathy were
seen in brain stem of the PDGF-a-Syn mice, followed
by more modest tauopathic changes in other brain
regions [Figure 2]. Thus, in the brain stem [Figure 2A],
p-Ser202 levels of Tau were significantly [p < 0.05]
increased by 73%, whereas p-Ser396/404 levels were
elevated by 43%, compared to litter-mate nontrans-
genic mice. These increases in p-Ser202 are lower than
those seen previously in the striatum [205% increase]
of the transgenic mice, and the increases in p-Ser396/
404 are also lower than those seen previously in
striata, where we had observed a 50-fold (5000%)
increase [33]. For p-Ser262, however, we observed a
25-fold (2500%) increase in brain stem, which was
much higher than the 255% increase we had previously
seen in the striatum [33].
In hippocampus [Figure 2B], significant increases were
seen for all three epitopes of p-Tau, and although the
levels of increases in p-Ser262 were much lower than
those seen in brain stem, p-Ser202 and p-Ser396/404
were higher than in brain stem. Thus, increases of 158
[p < 0.05], 56 [p < 0.01] and 592% [p < 0.01] were seen
for p-Ser202, p-Ser262 and p-Ser396/404, respectively,
in hippocampus.
In frontal cortex [Figure 2C], no changes were seen
for either p-Ser202 or p-Ser262, while p-Ser396/404 was
significantly [p < 0.01] increased by 425%. Similarly in
the cerebellum, we failed to observed changes in p-
Ser202 and p-Ser262, while significant [p <0 . 0 5 ]
increases of 299% were noted for p-Ser396/404.
Together, these data indicate that the tauopathy
observed in the various brain regions has the following
rank order of intensity: brain stem > hippocampus >
frontal cortex > cerebellum.
Immunohistochemical analysis of a-Syn and p-Tau
Staining was performed on brain slices and the follow-
ing brain regions were examined: striatum, frontal cor-
tex, cerebellum and brain stem, using antibodies against
a-Syn [Figure 3A] or p-Ser396/404 Tau [Figure 3B]. As
was shown in the Western blots [Figure 1 &2], both a-
Syn and p-Tau stain more intensely in the Tg mouse
brains than wild type. In Figure 3A, white arrows indi-
cate large cellular bodies staining positively for a-Syn in
the Tg versus WT specific brain regions. A similar pat-
tern of staining was seen for the specific brain regions
stained for p-Ser396/404 Tau (Figure 3B) where white
arrows indicate the presence of large cellular bodies
seen in the Tg but not the WT brain sections. More-
over, the highlighted bodies shown in the inset pictures
are reminiscent of the Lewy bodies commonly seen in
Parkinson’s disease brains.
Tau kinases in different brain regions of the PDGF-a-Syn
overexpressing mice
Tau is hyperphosphorylated by several kinases including
p-GSK-3b,p - J N K ,p - p 3 8 M A P K ,p - E R K ,c d k 5 ,c a l m o d u -
lin kinase and protein kinase A [38]. Of these, we have
previously found that p-GSK-3b was specifically acti-
vated by a-Syn in vitro in MPP+-treated SH-SY5Y cells
and mesencephalic primary neurons [31,29] and in vivo
in striata of MPTP-treated mice [32]. Moreover, block-
ade of p-GSK-3b with selective inhibitors or with
lithium [31,32] abrogated GSK-3b activation and Tau
hyperphosphorylation, suggesting a central role for this
kinase in a-Syn-mediated p-Tau formation in dopami-
nergic cells and neurons.
In the present study, we examined activated p-GSK-
3b levels [hyperphosphorylated at tyrosine 216] in the
different brain regions. The antibody we used recog-
nizes both the a-p-GSK-3b [upper band] and the b-p-
GSK-3b band of the kinase. Therefore, in all studies,
only the lower band was used in all calculations. In
striata, we had previously found p-GSK-3b levels were
significantly increased [by 112%, p <0 . 0 5 ]i nt h e
PDGF-a-Syn transgenic mice [33]. In brain stem [Fig-
u r e4 A ] ,w ef a i l e dt oo b s e r v ea n yi n c r e a s e si np - G S K -
3b l e v e l sa n di n s t e a df o u n dt h a tp - G S K - 3 b was signif-
icantly [p < 0.01] decreased by 70%. The decrease was
due to an overall increase in total GSK-3b levels [see
Figure 4A], so that when p-GSK-3b levels were com-
puted according to total GSK-3b levels, an overall net
decrease was seen. This was accompanied by
increases in levels of the inactive form of GSK-3b,
phosphorylated at Ser9, which leads to inactivation of
GSK-3b [data not shown]. In hippocampus [Figure
4A], no significant changes in p-GSK-3b or total
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Page 3 of 11Figure 2 Western blots of p-Tau levels in brain stem, hippocampus, frontal cortex, and cerebellum of PDGF-a-Syn overexpressing
transgenic mice. Brain stem, BS [A], hippocampus, HP [B], frontal cortex, FC [C] and cerebellum, CB [D] from PDGF-a-Syn transgenic mice and
litter-mate non-transgenic mice [WT] were solubilized in RIPA buffer and analyzed by Western blots for p-Tau levels. The following p-Taus were
normalized to total Tau: p-Ser202, p-Ser262, and p-Ser396/404. All values are expressed as percent change relative to changes observed in WT
control animals. Results are from 3-4 animals per group; [*, p < 0.05] and [**, p < 0.01] compared to corresponding protein levels in WT animals.
All blots are representative of samples.
Kaul et al. BMC Neuroscience 2011, 12:79
http://www.biomedcentral.com/1471-2202/12/79
Page 4 of 11GSK-3b were found compared to litter-mate non-
transgenic mice. Similarly, we also found no changes
in p-GSK-3b levels in either frontal cortex or in cere-
bellum [Figure 4A]. These combined data suggest that
unlike our findings in striata [33], where p-GSK-3b
was found to hyperphosphorylate Tau, in other brain
regions of the PDGF-a-Syn mouse, p-GSK-3b did not
participate in p-Tau formation and was not activated
by a-Syn.
We therefore tested other kinases, by focusing on the
mitogen-activated protein [MAP] family of kinases. In
all brain regions, we failed to see any activation of p-
p38MAPK [Figure 4B], eliminating a role for this kinase
in hyperphosphorylation of Tau; we were unable to
detect this protein in the brain stem, even in nontrans-
genic mice. When p-ERK levels were examined, signifi-
cant and robust increases in the levels of this enzyme
were seen in brain stem [114%, p < 0.01], hippocampus
[407%, p < 0.05] and frontal cortex [34%, p < 0.05], with
no changes in the cerebellum. These data suggest that
in other brain regions, p-ERK may play an essential role
in the hyperphosphorylation of Tau.
When p-JNK levels were examined [Figure 4D], large
increases in this kinase were seen in brain stem [874%,
p < 0.01], with nonsignificant changes seen in the hippo-
campus [32%] and frontal cortex [180%]. Small but sig-
nificant increases were also seen in the cerebellum [64%,
p < 0.05]. These data suggest that in the brain stem,
Tau may be hyperphosphorylated by both p-JNK and p-
ERK, while in hippocampus and frontal cortex tauopathy
may proceed entirely through p-ERK, but not through
p-JNK, activation. In cerebellum, tauopathic changes
m a yb em e d i a t e de n t i r e l yt h r o u g ht h ea c t i o no fp - J N K ,
but not p-ERK.
Figure 3 Immunostaining of a-Syn and p-Tau in WT and Tg mice. Immunohistochemical staining with (A) a-Syn, green, or (B) p-Tau, red,
using specific antibodies and DAPI, blue, was conducted as described in Methods. The brain regions pictured top to bottom are: Striatum - Str,
Frontal Cortex - FC, Cerebellum - CB, and Brain Stem - BS, in wild type (WT) left panel, and transgenic (Tg) right panel. Inset pictures show 4×
magnified region with arrows indicating positive staining of large cellular aggregates. Scale bar: 40 uM, Inset Scale bar: 10 uM.
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Page 5 of 11Figure 4 Western blots of p-GSK-3b, p-p38, p-ERK, and p-JNK levels in brain stem, hippocampus, frontal cortex, and cerebellum of
PDGF-a-Syn overexpressing transgenic mice. Brain stem [BS], hippocampus [HP], frontal cortex [FC], and cerebellum [CB] from PDGF-a-Syn
transgenic mice and litter-mate non-transgenic mice [WT] were solubilized in RIPA buffer and analyzed by Western blots for p-GSK-3b [A], p-p38
[B], p-ERK [C], and p-JNK [D]. p-GSK-3b was normalized to GSK-3b, p-p38 to p38, p-ERK to ERK, and p-JNK to JNK. p-p38MAPK was not detected
in brain stem and therefore this data is not shown. All values are expressed as percent change relative to changes observed in WT control
animals. Results are from 3-4 animals per group; [*, p < 0.05] and [**, p < 0.01] compared to corresponding protein levels in WT animals. All blots
are representative of samples.
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Page 6 of 11Elevated levels of free tubulin in brainstem of transgenic mice
Hyperphosphorylation of Tau at Ser262 reduces its affi-
nity for microtubules, causing it to dissociate from the
microtubular network, leading to destabilization of the
microtubules [39,38]. In striata of the PDGF-a-Syn
overexpressing transgenic,w eh a v ep r e v i o u s l ys h o w na
significant increase in soluble tubulin levels of 13%, indi-
cative of cytoskeleton remodeling in this brain region
[33]. To test whether the tauopathy seen in the different
brain regions of the transgenic mice also lead to micro-
tubule remodeling, we measured levels of free tubulin in
RIPA-soluble extracts [Figur e5 ] .I nb r a i ns t e m ,w es a w
large and significant increases of 391% [p < 0.01] in
tubulin levels in transgenic mice, compared to wild type
controls. In other brain regions, no significant changes
in tubulin levels were noted between wild type and
transgenic mice, except in frontal cortex, where a small
but significant [p < 0.05] decrease of 13% was noted.
The higher levels of soluble tubulin seen in the brain
stem parallels the higher levels of p-Ser262 Tau seen in
this brain region compared to other regions, and sug-
gests profound remodeling of the microtubular
cytoskeleton.
Discussion
We show here for the first time that an elevated state of
tauopathy exists in the brain stem of the PDGF-a-Syn
overexpressing mice, where high levels of p-Ser202, p-
Ser262 and p-Ser396/404. This was accompanied by
lower levels of tauopathy in the hippocampus. In cere-
bellum and frontal cortex, increases were seen for only
p-Ser396/404, but not for p-Ser202 or p-Ser262. The
severity of tauopathy, in general, is linked to parallel
increases in a- S y n .T h u s ,i nt h eb r a i ns t e m ,w h e r ew e
observed the most severe tauopathy, we also observed
the highest increases in a-Syn levels. By contrast, other
brain regions that showed lower increases in a-Syn
levels were also characterized by lower levels of tauopa-
thy. Our earlier studies have shown a tight linkage
between a-Syn and p-Tau levels, and we have shown a
mandatory requirement for a-Syn in tauopathy. Thus,
in a-Syn knock-out animals or in cells lacking a-Syn
[29], we fail to observe any tauopathic changes upon
treatment with PD-inducing neurotoxins. In AD, it is
long believed that the amyloid protein, b-amyloid, trig-
gers the cascade of events that leads to generation of p-
Tau. Similarly in the context of PD, emerging evidence
from our laboratory has identified a-Syn to be the amy-
loid protein triggering tauopathy.
There have been only limited studies identifying the
sites of hyperphosphorylation of Tau in PD brains. In
one of these, Tau was found to be hyperphosphorylated
at Ser396/404 in synaptic fractions from frontal cortex
of PD postmortem striata [40]. Studies from our own
laboratory have shown that Tau in striata of PD patients
is hyperphosphorylated at Ser202, Ser262 and Ser396/
404, where increases of 23, 34 and 81% were observed
in PD compared to control, non-diseased striata [35],
testifying to the pathophysiological relevance of these
sites. There are more than 45 sites of hyperphosphoryla-
tion of Tau identified in AD [38] and the molecular
consequences of only a few of these sites are known.
Tau is primarily located along axons and, in general,
hyperphosphorylation of Tau reduces its affinity for
Figure 5 Analyses of soluble tubulin in different brain regions. Soluble fractions of RIPA extracts prepared from different brain regions of
PDGF-a-Syn transgenic mice and wild type controls were analyzed for a-tubulin by Western blots as described in Methods. All values are
expressed as percent change relative to changes observed in WT control animals. Results are from 3-4 animals per group; [*, p < 0.05] and [**, p
< 0.01] compared to corresponding protein levels in WT animals. All blots are representative of samples.
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Page 7 of 11microtubules [MTs], leading to their destabilization,
with eventual degeneration of neurons. Hyperphosphor-
ylation at the microtubule MT binding domain [residues
244-368] of Tau is especially crucial in regulating MT
stabilization, and phosphorylation at Ser262 detaches
Tau from MTs, resulting in their destabilization [41].
Hyperphosphorylation at Ser396/404 promotes self
assembly of Tau to form aggregates of Tau [39]. More-
over, in vitro studies using Tau peptides showed that
phosphorylation of Tau at Ser262 and Ser356 modified
both the negative charge and the local conformation
near the phosphorylation sites, reducing the affinity of
the peptides to bind to MTs [42]. Therefore, our finding
of very high levels of p-Ser262 in the brain stem may
explain the increased levels of soluble a-tubulin seen in
this brain region. By contrast, the other brain regions
had either no [frontal cortex and cerebellum] or low
increases in p-Ser262 levels [hippocampus], and, there-
fore, also had no changes in soluble a-tubulin.
The pattern of tauopathy observed in this mouse
model of PD closely parallels the Braak synucleinopathic
staging scheme of Parkinson’s disease initially proposed
by Braak et al. [37]. Thus, it has been proposed that
lesions initially occur in the glossopharyngeal and vagal
nerves and in the anterior olfactory nucleus, progressing
to the brain stem, and thereafter pursuing an ascending
course of pathology [37]. Cortical involvement follows,
beginning with the anteromedial temporal mesocortex,
followed by the neocortex, especially the prefrontal
region. The concept proposed by Braak and colleagues
[37] that lower brainstem synucleinopathy represents
“early PD”, subsequently progressing within the human
lifetime to involve the mesencephalon, suggests that the
brain stem may be more severely affected than dopami-
nergic neurons, and this is borne out by the higher
degree of tauopathy seen in the brain stem compared to
the striatum in the PDGF-a-Syn overexpressing mice.
Indeed, our findings of higher levels of soluble a-tubulin
in the brain stem of the transgenic mouse as compared
to the wild type also occurs in parallel with the higher
levels of synucleinopathy seen in this brain region, sug-
gesting that the brain stem is undergoing more degen-
eration than any other brain region tested.
Unlike our previous findings, the current study does
not indicate any involvement of p-GSK-3b in the accu-
mulation of p-Tau in brain regions other than the stria-
tum. Previously, we had found that a-Syn could recruit
and activate p-GSK-3b in a specific manner in the stria-
t u m[ 3 2 , 3 5 ]a n dt h a ts u c ha c t i v a t i o no fp - G S K - 3 b was
dependent on autoxidation of dopamine [34]. The cur-
rent study suggests that in non-dopaminergic neurons,
other kinases may instead become activated. Thus, our
data suggest that p-ERK and p-JNK, but not p-
p38MAPK, become activated. To our knowledge, this is
the first report of a possible involvement of p-ERK and
p-JNK in the genesis of tauopathy in PD. Thus,
increased levels of p-ERK are seen in brain stem, hippo-
campus and frontal cortex, but not in cerebellum, indi-
cating the possible participation of this kinase in the
first three brain regions mentioned. Indeed, in both PD
striata and in cellular as well as animal models of PD,
ongoing studies in our laboratory suggest an important
and central role for p-ERK in the pathogenesis of PD
[Duka & Sidhu, Unpublished Observations]. Since p-
JNK is activated in cerebellum, it is likely that the
increase in p-Ser396/404 seen here proceeds through p-
JNK. By contrast, the increase in tauopathy seen in hip-
pocampus is likely to occur entirely through p-ERK and
not p-JNK, since p-JNK is not activated in this region.
In brain stem, however, the high levels of both p-ERK
and p-JNK may together contribute to the very high
levels of tauopathy seen in this region. It should be
noted, however, that our results do not eliminate the
possibility that other kinases may also participate in
hyperphosphorylation of Tau, either in concert with, or
entirely independent of, p-ERK and p-JNK.
It is now well established that overexpression of a-
Syn, through its gene duplication and triplication, is
linked to idiopathic Parkinson’s disease [43,9], although
the mechanism[s] by which PD occurs in such popula-
tions remains elusive. The PDGF-a-Syn overexpressing
mouse model closely mimics sporadic PD [36] and our
data show that at least part of the mechanism may be
due to tauopathic changes in not only the striatum of
these mice [33] but also in other brain regions, such as
the brain stem, hippocampus, frontal cortex and cerebel-
lum. Therapy aimed at reducing the overall tauopathic
burden may be especially useful in alleviating PD.
Conclusion
In summary, our studies show that in the a-Syn overex-
pressing mouse model of PD, tauopathy occurs in parallel
to synucleinopathy. In brainstem, which has the highest
levels of a-Syn, the highest levels of tauopathy were also
seen, which was accompanied by elevated levels of soluble
a-tubulin. In other brain regions, lower levels of a-Syn
also gave rise to lower levels of tauopathy, without any
increases in a-tubulin. The major Tau kinase, GSK-3b,
was not activated in any of the brain regions examined.
Instead, activation of both p-ERK and p-JNK was variably
seen implicating these kinases in the genesis of PD.
Materials and methods
Materials
T h ea n t i b o d i e su s e di nt h i ss t u d ya r e :a n t i - T a u
MAB361 from Millipore [Temecula, CA]; anti-Tau
Neurofibrillary Tangles Marker AHB0042 and anti-Tau
(p-S262), Biosource Invitrogen [Carlsbad, CA]; anti-a-
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Page 8 of 11Syn CAT# 610787, anti-GSK-3b CAT# 612313 and
anti-p-GSK-3b [purified mouse anti-GSK-3b (pY216)
CAT # 612313], from BD Transduction Labs [San Jose,
CA]; anti-a-Tubulin T6074 from Sigma-Aldrich [St.
Louis, MO]; anti-b-actin SC-1616 from Santa Cruz
Biotechnology, Inc. [Santa Cruz, CA]; The CP-13 and
PHF-1 [recognizing Tau-Ser202 and Tau-Ser396/404,
respectively] were gifts from Dr. Peter Davies [New
York]; GAPDH [14C10 #2118], p-ERK [Phospho-p44/
42 MAPK (Erk1/2) (Thr202/Tyr204) (E10) #9106],
ERK [p44/42 MAPK (Erk1/2) (137F5) #4695], p-p38
[Phospho-p38 MAPK (Thr180/Tyr182) (28B10) #9216],
p38 MAPK [#9212], p-SAPK/JNK [Phospho-SAPK/JNK
(Thr183/Tyr185) (G9) #9255], and SAPK/JNK [#9252]
were all from Cell Signaling Technology [Danvers,
Massachusetts].
Animals
All studies with animals were conducted under strict
guidelines of the National Institutes of Research and
were approved by Georgetown University Animal Care
and Use Committee. Hemizygous mice overexpressing
a-Syn driven by the platelet-derived growth factor
[PDGF] promoter were imported (from E. Masliah, Uni-
versity of California San Diego, CA). For all experi-
ments, hemizygous PDGF-a-Syn mice were bred with
wild type (WT) mice (C57BL/6 × DBA/2 F1; B6D2F1/J)
obtained from Jackson Labs to produce both WT and
PDGF-a-Syn littermates, and a breeding colony was
established as described previously [36].
Western Blot Analysis
Western blot analysis was performed as described else-
where [32,35]. Briefly, mouse brain stem, hippocampus,
frontal cortex, and cerebellum from 11 month old WT
and Tg animals were homogenized in RIPA buffer (50
mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM EDTA) con-
taining 0.5% Triton X-100, 0.5% sodium deoxycholate,
and 0.1% SDS in the presence of protease inhibitor cock-
tail tablets (Complete Mini, EDTA-free; Roche Diagnos-
tics GmbH, Germany) and phosphatase inhibitor cocktail
(Halt™ Protease Inhibitor Cocktail; Pierce). Lysates were
inverted at 4°C for 30 min, followed by centrifugation for
10 min at 15,000 × g and 4°C. Supernatants were col-
lected and protein concentrations were measured using
the MBLowry assay. Samples were analyzed by Western
blots on 10-20% Tris-HCl Criterion gels (Bio-Rad), after
blocking with 20 mM Tris-buffered saline, pH 7.6 con-
taining 0.1% Tween 20 (TBST) and 5% (wt/vol) blotting
grade blocker non-fat dry milk (Bio-Rad) for 1 hour at
room temperature. Western blots were developed with a
wide range of specific human Tau antibodies that recog-
nize the protein at different phosphorylation sites, includ-
ing: CP13 (p-Ser202) (1:500), PHF-1 (p-Ser396/404)
(1:1000) and p-Ser262 (1:500). Total Glycogen Synthase
Kinase-3b (GSK-3b) was probed for with mouse GSK-3b
antibody (1:500) and phospho-GSK-3b was probed for
using mouse phospho-specific (pY216) antibody (1:500).
a-Tubulin levels in RIPA-solubilized lysates was probed
for with mouse a-tubulin antibody (1:4000). To probe for
a-Syn, samples were run on 10-20% Tris HCl Criterion
gels (Bio-Rad) and immunoblotted with mouse a-synu-
clein (1:1000) antibody. All proteins were normalized to
total Tau (1:1000), b-actin (1:500) or GAPDH (1:1000).
After incubation for 2 hours at room temperature with
HRP-conjugated secondary antibodies (1:3000, Santa
Cruz), proteins were revealed by enhanced chemilumi-
nescence (Perkin Elmer). Images were scanned by Scan-
ner EPSON Perfection V700 Photo and then quantified
using ImageJ.
Immunohistochemistry
IHC analysis of mouse brain coronal sections was per-
formed as previously described [33], with slight modi-
fications. Briefly, mouse brains from 11 month old
control wild-type and age-matched Tg a-Syn mutant
mice were perfused with 4% PFA, and prepared in a
sequential sucrose gradient, from 10% to a final 30%
sucrose soak. Sections (5 μm) were washed, permeabi-
lized, and stained in the following manner. Each slice
was washed 3 times in 1 mg/ml NaBr2,1×P B Sp H
7.4, for 5 min at room temperature. Following the
NaBr2 auto-fluorescence quenching treatment, each
slice was washed 6×, for 10 min in 1 × PBS pH 7.4,
1% Triton X-100 followed by blocking for 1 hr at
room temperature in 1 × PBS pH 7.4, 1% Triton X-
100, 10% FCS. Incubation with primary antibody
occurred at 4°C, overnight in the dark, in blocking
buffer using the following concentrations of antibo-
dies: anti-a-Syn, 1:750; PHF-1, 1:500. Following stain-
ing, each slice was washed 3 × in 1 × PBS pH 7.4, 1%
Triton X-100 at room temperature, incubated for 30
min in blocking buffer, and washed a final 3× in 1 ×
PBS pH 7.4, 1% Triton X-100 before incubation with
appropriate secondary antibody; goat anti-mouse
alexa-fluor 594, goat anti-mouse alexa-fluor 488, at
the a concentration of 1:500. Following staining with
secondary antibody, each slice was washed 3 × in 1 ×
PBS pH 7.4, 1% Triton X-100 at room temperature.
Stained slices were mounted to Fischer Scientific
Superfrost standard microscope slides using Fluoro-
mount-DAPI. Fluorescence images were captured
using a laser scanning confocal microscope (Olympus
FV300). Paired images between WT and Tg tissue for
all figures were collected at the same laser power,
gain, and offset settings. Post-collection processing
was performed using ImageJ and applied uniformly to
all paired images.
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Results were expressed as mean ± S.E.M. and statisti-
cally analyzed by the Student’s t-test between two
groups. Statistical significance was accepted at the [p <
0.05] level.
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